Compare LMND & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMND | BLLN |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.4B |
| IPO Year | 2020 | 2025 |
| Metric | LMND | BLLN |
|---|---|---|
| Price | $52.96 | $96.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $70.86 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 947.0K | 768.8K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.40 | ★ 103.40 |
| EPS | N/A | ★ 0.48 |
| Revenue | ★ $737,900,000.00 | $305,112,000.00 |
| Revenue This Year | $65.20 | $46.29 |
| Revenue Next Year | $33.31 | $30.14 |
| P/E Ratio | ★ N/A | $192.33 |
| Revenue Growth | 40.15 | ★ 99.97 |
| 52 Week Low | $46.16 | $61.96 |
| 52 Week High | $99.90 | $150.44 |
| Indicator | LMND | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 46.71 | 43.79 |
| Support Level | $52.26 | $79.07 |
| Resistance Level | $54.40 | $101.62 |
| Average True Range (ATR) | 1.97 | 4.47 |
| MACD | 0.42 | 0.52 |
| Stochastic Oscillator | 53.10 | 61.63 |
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. The Company operates in one report segment providing personal property and casualty insurance products within the United States and Europe, including the UK.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.